Anika Therapeutics
ANIK
170 hedge funds and large institutions have $446M invested in Anika Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 63 increasing their positions, 51 reducing their positions, and 24 closing their positions.
159% more call options, than puts
Call options by funds: $5.83M | Put options by funds: $2.25M
24% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 51
10.26% more ownership
Funds ownership: 84.28% → 94.54% (+10%)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
0% more funds holding
Funds holding: 170 → 170 (0)
28% less capital invested
Capital invested by funds: $616M → $446M (-$169M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$18.7M |
| 2 |
Morgan Stanley
New York
|
+$17.8M |
| 3 |
EC
Engaged Capital
Newport Beach,
California
|
+$10.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.71M |
| 5 |
BlackRock
New York
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$27.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.03M |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$4.41M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$2.67M |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$1.81M |
ANIK Hedge Fund Activity: Q2 2018 in Review
170 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2018, worth a combined $446M — down 28% from $616M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ANIK positions and 24 closed out — a net gain of 2 holders — while 63 added to existing stakes and 51 trimmed.
The largest buyer was First Manhattan, adding an estimated $18.7M. The largest seller was Wellington Management Group, cutting an estimated $27.4M.
- 170 institutional investors held Anika Therapeutics (ANIK) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $446M of Anika Therapeutics stock for Q2 2018, down 28% quarter-over-quarter.
- 26 funds opened new Anika Therapeutics positions in Q2 2018 and 24 closed out, a net change of +2 holders.
- The largest Anika Therapeutics buyer in Q2 2018 was First Manhattan, an estimated $18.7M added.
- The largest Anika Therapeutics seller in Q2 2018 was Wellington Management Group, an estimated $27.4M sold.
Based on aggregated 13F filings for Q2 2018.